Tag Archives: cancer research

How to Starve Cancer Getting Fuel from Fat Cells

Cancer research is now going beyond the genetic aspect to explore how the disease interacts with the body’s systems. Recent studies of the relationship between cancer and fat cells may have implications concerning immunotherapy for cancer.

Feeding the Growth of Cancer Cells

While the precise causes are not yet known, obesity has been identified as a risk factor for prostate cancer, which is the second leading cause of cancer-related deaths in men. As a result, research into the link between cancer and fat cells has focused on this form of the disease.

Previous tests involved mice who were fed a high-fat diet. In contrast, researchers at Sanford Prebys Medical Discovery Institute in San Diego conducted a study using mice who lacked a protein called p62, causing them to become obese on a normal diet.

According to co-author Dr. Jorge Moscat, this control was necessary to get a clear understanding of the communication pathways between cancer and fat cells. The team discovered that p62 suppresses another protein known as mTORC1, which in turn inhibits energy use by fat cells.

Can Cancer Cells Be “Starved” to Death?

With metabolism halted in fat cells, nutrients are then available to fuel development of tumor cells. Lack of p62 also triggers production of proteins found at high levels in particularly aggressive forms of prostate cancer.

As explained by Dr. Moscat, these findings can help identify specific substances to be targeted by immunotherapy for cancer treatments with the goal of “starving” cancer cells.

State-of-the-Art Immunotherapy for Cancer at Issels®

Contact Issels® for information about our non-toxic, personally developed immunotherapy programs to treat advanced and therapy-resistant cancers.

Gas Embolotherapy Combined with Ultrasound May Block Cancer Tumor’s Blood Supply

New Cancer Treatments Are Being Studied Worldwide
New Cancer Treatments Are Being Studied Worldwide

Scientists are constantly searching for methods of cancer treatment that will kill tumor cells without affecting healthy tissue, thereby avoiding common side effects. A research team recently found that bubbles may be a surprising vehicle for starving tumors and delivering anti-cancer drugs.

“Starving” Cancer Cells

Tumor cells rely on a steady blood supply to furnish oxygen and nutrients required to multiply and spread to other parts of the body. In its absence, tumors use a process called angiogenesis to create new blood vessels.

Scientists had previously created a class of drugs known as angiogenesis inhibitors, which effectively halt blood vessel development. Embolization is an alternate method that incorporates drugs or nano-sized beads to block blood vessels.

A Non-Surgical Option to Defeat Cancer?

Gas embolization is a variation in which bubbles are used to create a blockage. Prof. Yi Feng and a team of scientists at Xi’an Jiaotong University in China conducted a study using blood vessel-rich intestinal tissue from rats.

In the first step, droplets of dodecafluoropentane, a fluorocarbon often used for conversion to gas microbubbles, were injected into the blood vessels. An ultrasound was then applied in a technique known as acoustic droplet vaporization (ADV).

As a result, the droplets formed bubbles that congregated in an area, with some of them uniting to create larger bubbles, effectively blocking the blood vessels. The team is hopeful that gas embolotherapy may eventually be used as a “double punch” attack on cancer.

Immunotherapy: Individually Created Cancer Treatment

For years, Issels® has helped patients with our non-toxic cancer treatment programs that boost the body’s own immune system. Visit our website for more information.

New Understanding on How Cancer Cells Provide for Tumor Growth and Metastasis

New Understanding on How Cancer Cells Provide for Tumor Growth and Metastasis
New Understanding on How Cancer Cells Provide for Tumor Growth and Metastasis

At Issels®, our immunotherapy for cancer treatments have helped patients with metastatic tumors achieve long-term remission. A recent discovery by scientists at the University of Wisconsin-Madison holds promise for developing a means to prevent the spread of cancer.

Exosomes: The Allies of Cancer Cells

Immunotherapy is aimed at helping the body’s immune system circumvent ways in which cancer cells avoid detection. One such method involves exosomes, which are protein-packed bags of fluid released by cancer cells.

Exosomes are powerful enough to affect the environment of cancer cells and divert the immune system, allowing cancer to spread to other areas in a process known as metastasis. The team at UW-Madison identified a protein called Munc13-4 that controls the release of exosomes.

Stopping the Spread of Cancer

According to the study, published in Journal of Cell Biology, Munc13-4 activates once it binds with calcium, which is frequently found at elevated levels in tumor cells. While calcium triggers exosome secretion in breast cancer, once the scientists removed Munc13-4. the secretion was halted.

The exosomes in the breast cancer cells contained an enzyme called MT1-MMP which breaks down the extracellular matrix, creating an environment that encourages the spread of cancer. Prof. Thomas F. J. Martin, senior author of the study, explained that by targeting Munc13-4, immunotherapy for cancer treatments could potentially prevent metastasis.

How Issels® Fights Advanced and Therapy-Resistant Tumors

Immunotherapy for cancer has been in the spotlight recently, but our successful use of these personally developed programs dates back to the work of our founder, Dr. Josef M. Issels. Contact us to learn more about cancer vaccines and other integrated treatments.

Tel Aviv University Nanoprobes Light Up Stray Cancer Cells

New Cancer Research Is Improving Cancer Treatment
New Cancer Research Is Improving Cancer Treatment

While cancer treatment often includes surgery, even a few missed cells can lead to recurrence and metastasis. Recent development of a “smart probe” that pinpoints cancer cells may greatly improve the effectiveness of surgical options.

Challenges of Surgery as Cancer Treatment

Removal of solid tumors can still leave behind stray cells that evade detection by MRI or CT. In some cases, surgeons end up damaging otherwise healthy tissue in an effort to excise all diseased cells.

Extensive studies by an interdisciplinary team at Tel Aviv University culminated in development of a nanoprobe that literally shines a light on cancer cells. When injected into a patient a few hours before surgery begins, the probe can alert the surgeon to the presence of cancer cells that might have been missed.

“Shedding a Light” on Cancer Cells

The probe is activated by the presence of an enzyme known as cysteine cathepsins, which occurs in higher numbers in tumor cells than in healthy cells. When the probe identifies cancerous cells, it triggers a fluorescent signal in those areas, while healthy tissue remains dark.

In tests conducted on mice with melanoma and breast cancer, the survival rate of mice that underwent probe-assisted surgery was double that of the mice who received regular surgery. Now that the team has registered patents for the technology, the next step is to start clinical trials with hopes of commercially marketing the probe.

Issels®: The Leader in Personally Developed Cancer Treatment

Our comprehensive cancer treatment programs incorporate a wide range of methods in order to address each patient’s individual needs. Contact us to learn more about the “Issels® Difference.”

Modified Polio Virus to be Tested In Brain Cancer Research Efforts

Issels the Premier Provider of Immuno Oncology
Issels the Premier Provider of Immuno Oncology

When it comes to your health, a virus is generally something to be avoided. In a surprising discovery, a virus that normally causes paralysis may hold promise as an immunotherapy for cancer treatment.

Can a Virus Actually Fight a Tumor?

Glioblastoma is the most common and most deadly form of brain cancer affecting adults. It gained a measure of public awareness after former Sen. Edward Kennedy and Beau Biden, son of former Vice President Joe Biden, succumbed to the disease. One year ago Sen. John McCain, already a cancer survivor, was diagnosed with glioblastoma.

Poliovirus, which causes the paralyzing disease that shares its name, infects cells in the nervous system. Based on this feature, a team of Duke University scientists decided to test a genetically modified version on patients with treatment-resistant glioblastoma.

Poliovirus and the Immune System: A Two-Pronged Attack

The researchers neutralized the virus by replacing the specific gene that causes polio with one from rhinovirus, which generally causes head colds. Once infused directly into the tumors, the newly formed virus was able to infect and kill cancer cells as well as stimulate the immune system to attack the cells.

According to team member Dr. Darell Bigner, the group’s 21 percent survival rate after three years is more than five times that of a previously treated comparison group. The researchers are planning to conduct studies combining the modified poliovirus with other immunotherapy for cancer drugs in hopes of improving the results.

Treatment for Advanced and Therapy-Resistant Cancers

Our Issels® immunotherapy for cancer programs have helped a number of patients when other treatments have failed. Contact us for more information.

New Immunotherapy Drug Combination Fails to Stop Cancer’s Progression

New Immunotherapy Drug Combination Fails to Stop Cancer's Progression
New Immunotherapy Drug Combination Fails to Stop Cancer’s Progression

Scientists have embraced immuno oncology research as an avenue for more effective cancer treatments. Unfortunately, the field took a temporary hit recently when Incyte pulled the plug on its latest immunotherapy drug trial.

Arming the Body’s Immune System

Incyte had high hopes for epacadostat, which works as an IDO inhibitor. IDO is an enzyme found in the body that prevents T cells in the immune system from attacking cancer cells.

In the trial, epacadostat was paired with Keytruda, a phenomenally successful immunotherapy drug from Merck. Keytruda is a checkpoint inhibitor that helps T cells recognize cancer cells, which often evade detection.

It was hoped that epacadostat would boost the effectiveness of Keytruda when taken alone. But not only did epacadostat fail to stop the progression of cancer, it had no positive effect on overall survival rates.

Is There Still Hope for Epacadostat?

While the original trial failed against melanoma, Incyte is hoping to conduct further tests with epacadostat in treating other forms of cancer. As explained by Dr. Jason Luke, an oncologist at the University of Chicago, the patient sample may have been too broad.

According to Dr. Luke, immunotherapy benefits patients with T cell-inflamed tumors. The key is to test epacadostat on patients who have a natural immune response, which can be determined via RNA-based sequencing.

Yale University oncologist Dr. Roy Herbst says the setback will not affect the enthusiasm for immunotherapy. He emphasizes that these cancer treatments are not a one-size-fits-all solution.

Personalized Immuno Oncology Programs at Issels®

Our non-toxic immunotherapy programs have always been tailored individually to address each patient’s specific needs. Contact us for more information.